{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:00Z","timestamp":1784557020597,"version":"3.55.0"},"reference-count":17,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"\n Summary<\/jats:title>\n We report the case of a 69-year-old female with systemic mastocytosis, diagnosed based on widespread pigmented papules and macules, elevated serum tryptase levels and confirmatory skin and bone marrow biopsy, on a background of osteoporosis. A CT demonstrated multiple sclerotic lesions within lumbar vertebral bodies, sacrum and ileum, with surrounding osteolysis but no obvious compression fractures. She was treated with the RANK-L inhibitor denosumab, resulting in significant bone mineral density gain over the following 5 years. However, her serum tryptase levels gradually increased during this period despite treatment with the multikinase inhibitor, midostaurin. It is thus conceivable that her rapid increase in bone mineral density may be partly contributed by a predominance of pro-osteoblastic mediators released by abnormal mast cells, suggestive of more advanced disease. This case highlights the complexities of systemic mastocytosis-related bone disease and the interplay of numerous mediators contributing to a phenotype of both increased bone resorption and formation.<\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n \n Systemic mastocytosis is a neoplastic disease of mast cells characterized by abnormal proliferation and accumulation in the skin and other organs. It is most frequently associated with the somatic gain-of-function\n KIT<\/jats:italic>\n D816V mutation.\n <\/jats:p>\n <\/jats:list-item>\n \n Systemic mastocytosis should be suspected in patients presenting with not only cutaneous symptoms suggestive of mast cell degranulation such as anaphylaxis, flushing or urticaria but also unexplained osteoporosis and gastrointestinal and constitutional symptoms.<\/jats:p>\n <\/jats:list-item>\n \n The prevalence of osteoporosis in systemic mastocytosis is high. Mast cell activation leads to the secretion of numerous chemical mediators which either promote or inhibit osteoclastic and\/or osteoblastic activity, with the balance usually in favour of increased bone resorption. However, in advanced diseases with high mast cell burden, mast-cell-derived cytokines and mediators may promote osteoblastic activity, leading to osteosclerosis and apparent increases in bone mineral density.<\/jats:p>\n <\/jats:list-item>\n \n Treatment of osteoporosis in systemic mastocytosis involves antiresorptive therapy with bisphosphonates and more recently, denosumab. There are limited data on the role of osteoanabolic agents.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-22-0408","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T11:34:35Z","timestamp":1683804875000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":5,"title":["Skin and bones: systemic mastocytosis and bone"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-5117","authenticated-orcid":true,"given":"Mawson","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J","family":"Seibel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia"},{"name":"Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"American Journal of Hematology","first-page":"508","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. American Journal of Hematology202196508\u2013525. (https:\/\/doi.org\/10.1002\/ajh.26118)"},{"key":"bib2","series-title":"Annual Review of Medicine","first-page":"419","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","unstructured":"Akin C & Metcalfe DD. Systemic mastocytosis. Annual Review of Medicine200455419\u2013432. (https:\/\/doi.org\/10.1146\/annurev.med.55.091902.103822)"},{"key":"bib3","series-title":"New England Journal of Medicine","first-page":"2530","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","unstructured":"Gotlib JKluin-Nelemans HCGeorge TIAkin CSotlar KHermine OAwan FTHexner EMauro MJSternberg DW, Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine20163742530\u20132541. (https:\/\/doi.org\/10.1056\/NEJMoa1513098)"},{"key":"bib4","series-title":"Frontiers in Immunology","article-title":"The role of mast cells in bone metabolism and bone disorders","volume":"11","author":"Ragipoglu","year":"2020","unstructured":"Ragipoglu DDudeck AHaffner-Luntzer MVoss MKroner JIgnatius A & Fischer V. The role of mast cells in bone metabolism and bone disorders. Frontiers in Immunology202011 163. (https:\/\/doi.org\/10.3389\/fimmu.2020.00163)"},{"key":"bib5","series-title":"Immunology and Allergy Clinics of North America","first-page":"383","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","unstructured":"Rossini MZanotti RViapiana OTripi GOrsolini GIdolazzi LBonadonna PSchena DEscribano LAdami S, Bone involvement and osteoporosis in mastocytosis. Immunology and Allergy Clinics of North America201434383\u2013396. (https:\/\/doi.org\/10.1016\/j.iac.2014.01.011)"},{"key":"bib6","series-title":"Reviews in Endocrine and Metabolic Disorders","first-page":"419","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","unstructured":"Greene LWAsadipooya KCorradi PF & Akin C. Endocrine manifestations of systemic mastocytosis in bone. Reviews in Endocrine and Metabolic Disorders201617419\u2013431. (https:\/\/doi.org\/10.1007\/s11154-016-9362-3)"},{"key":"bib7","series-title":"Journal of Allergy and Clinical Immunology","first-page":"1234","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","unstructured":"Rabenhorst AChristopeit BLeja SGerbaulet AKleiner SF\u00f6rster ARaap UWickenhauser C & Hartmann K. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. Journal of Allergy and Clinical Immunology20131321234\u20131237.e7. (https:\/\/doi.org\/10.1016\/j.jaci.2013.06.019)"},{"key":"bib8","series-title":"Allergy","first-page":"431","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","unstructured":"van der Veer Evan der Goot Wde Monchy JGKluin-Nelemans HC & van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy201267431\u2013438. (https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02780.x)"},{"key":"bib9","series-title":"Osteoporosis International","first-page":"2411","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","unstructured":"Rossini MZanotti ROrsolini GTripi GViapiana OIdolazzi LZam\u00f2 ABonadonna PKunnathully VAdami S, Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporosis International2016272411\u20132421. (https:\/\/doi.org\/10.1007\/s00198-016-3539-1)"},{"key":"bib10","series-title":"Bone","first-page":"880","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","unstructured":"Rossini MZanotti RBonadonna PArtuso ACaruso BSchena DVecchiato DBonifacio MViapiana OGatti D, Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone201149880\u2013885. (https:\/\/doi.org\/10.1016\/j.bone.2011.07.004)"},{"key":"bib11","series-title":"American Journal of Medicine","first-page":"75.e1","article-title":"Bone complications of mastocytosis: a link between clinical and biological characteristics","volume":"126","author":"Guillaume","year":"2013","unstructured":"Guillaume NDesoutter JChandesris OMerlusca LHenry IGeorgin-Lavialle SBarete SHirsch IBouredji DRoyer B, Bone complications of mastocytosis: a link between clinical and biological characteristics. American Journal of Medicine201312675.e1\u201375.e7. (https:\/\/doi.org\/10.1016\/j.amjmed.2012.07.018)"},{"key":"bib12","series-title":"Age and Ageing","first-page":"1","article-title":"Bone density, bone markers and bone radiological features in mastocytosis","volume":"25","author":"Johansson","year":"1996","unstructured":"Johansson CRoupe GLindstedt G & Mellstr\u00f6m D. Bone density, bone markers and bone radiological features in mastocytosis. Age and Ageing1996251\u20137. (https:\/\/doi.org\/10.1093\/ageing\/25.1.1)"},{"key":"bib13","series-title":"Lancet. Diabetes and Endocrinology","first-page":"513","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension","volume":"5","author":"Bone","year":"2017","unstructured":"Bone HGWagman RBBrandi MLBrown JPChapurlat RCummings SRCzerwi\u0144ski EFahrleitner-Pammer AKendler DLLippuner K, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension. Lancet. Diabetes and Endocrinology20175513\u2013523. (https:\/\/doi.org\/10.1016\/S2213-8587(1730138-9)"},{"key":"bib14","series-title":"Journal of Cancer Research and Clinical Oncology","first-page":"945","article-title":"An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis","volume":"146","author":"Riffel","year":"2020","unstructured":"Riffel PSchwaab JLutz CNaumann NMetzgeroth GFabarius ASchoenberg SOHofmann WKValent PReiter A, An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. Journal of Cancer Research and Clinical Oncology2020146945\u2013951. (https:\/\/doi.org\/10.1007\/s00432-019-03119-3)"},{"key":"bib15","series-title":"American Journal of Medicine","first-page":"1127.e1","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","unstructured":"Rossini MZanotti RViapiana OTripi GIdolazzi LBiondan MOrsolini GBonadonna PAdami S & Gatti D. Zoledronic acid in osteoporosis secondary to mastocytosis. American Journal of Medicine20141271127.e1\u20131127.e4. (https:\/\/doi.org\/10.1016\/j.amjmed.2014.06.015)"},{"key":"bib16","series-title":"Calcified Tissue International","first-page":"595","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: A case series","volume":"100","author":"Orsolini","year":"2017","unstructured":"Orsolini GGavioli ITripi GViapiana OGatti DIdolazzi LZanotti R & Rossini M. Denosumab for the treatment of mastocytosis-related osteoporosis: A case series. Calcified Tissue International2017100595\u2013598. (https:\/\/doi.org\/10.1007\/s00223-017-0241-z)"},{"key":"bib17","series-title":"Calcified Tissue International","first-page":"410","article-title":"Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis","volume":"96","author":"Rossini","year":"2015","unstructured":"Rossini MViapiana OZanotti RTripi GPerbellini OIdolazzi LBonifacio MAdami S & Gatti D. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcified Tissue International201596410\u2013416. (https:\/\/doi.org\/10.1007\/s00223-015-9969-5)"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/2\/EDM22-0408.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/2\/EDM22-0408.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/2\/EDM22-0408.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:09Z","timestamp":1784555289000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":17,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/edm-22-0408","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}